Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 5/20 | 0.65 |
| ▸ | TLR2 | O60603 | 5/20 | 0.65 |
| ▸ | FBP1 | P09467 | 12/20 | 0.56 |
| ▸ | VCP | P55072 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21482523 | 0.82 | TLR4 (0.54) | TLR4TLR2FBP1VCPEGFR | |
| SCHEMBL12635599 | 0.81 | FBP1 (0.79) | TLR4TLR2FBP1VCPEGFR | |
| SCHEMBL510018 | 0.79 | TLR4 (1.00) | TLR4TLR2FBP1EGFRERBB2 | |
| SCHEMBL510019 | 0.79 | TLR4 (1.00) | TLR4TLR2FBP1EGFRERBB2 | |
| SCHEMBL15516304 | 0.76 | HSPB1 (0.62) | — | |
| SCHEMBL21486341 | 0.76 | NFE2L2 (0.40) | TLR4TLR2 | |
| SCHEMBL505416 | 0.75 | ALDH1A1 (0.50) | — | |
| SCHEMBL18533681 | 0.75 | FBP1 (0.68) | TLR4TLR2FBP1VCPEGFR | |
| SCHEMBL6910815 | 0.74 | FBP1 (0.78) | TLR4TLR2FBP1VCPEGFR | |
| SCHEMBL6910818 | 0.74 | FBP1 (0.78) | TLR4TLR2FBP1VCPEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147428-A1 | METHOD FOR PREPARING PYRROLOAMINOPYRIDAZINONE COMPOUND AND INTERMEDIATES THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-05-20 | — | — | US | disclosed |
| WO-2021057998-A1 | PREPARATION METHOD FOR PYRROLOAMINOPYRIDAZINONE COMPOUND | 上海森辉医药有限公司 | 2021-04-01 | — | — | WO | disclosed |
| EP-3778591-A1 | METHOD FOR PREPARING PYRROLOAMINOPYRIDAZINONE COMPOUND AND INTERMEDIATES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019196915-A1 | METHOD FOR PREPARING PYRROLOAMINOPYRIDAZINONE COMPOUND AND INTERMEDIATES THEREOF | 江苏恒瑞医药股份有限公司 | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147428-A1 | METHOD FOR PREPARING PYRROLOAMINOPYRIDAZINONE COMPOUND AND INTERMEDIATES THEREOF | DHPS, PPOX, PNPO | TLR4 3371/4885TLR2 4629/4885FBP1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.